Move of the month
Chiesi Farmaceutici hires new CEO after $1.48bn Amryt acquisition
Chiesi Farmaceutici, a family-owned Italian pharmaceutical company, has appointed Giuseppe Accogli as group CEO. This comes after 2020’s $1.48bn acquisition of rare disease specialist Amryt.
Accogli has 25 years’ experience in the pharma industry, most recently at Baxter in its renal sector. Before then, he was at Italian medtechs Medtronic and Tyco Healthcare. Accogli’s background spans sales, marketing, product innovation, R&D and M&A, where he focused on the EMEA and US markets.
Giuseppe Accogli stated: “I am honoured to lead Chiesi into its new stages of growth and I thank the Board of Directors for their trust and the opportunity they are giving me to be part of such an exciting journey. At its core, Chiesi is a group of innovative and highly committed professionals who care for the health and well-being of people around the world leaving a positive impact in the environment and the communities in which the company operates. As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling this commitment to be a sustainable force for good in the biopharmaceutical industry.”
Alberto Chiesi, President of Chiesi Group, says, “We are thrilled to have Giuseppe in the CEO role. He is a proven leader with the vision and the strength to expand on the success Chiesi has built over the past 85 years and take us into our next phase of growth and innovation.”
Amryt, another Italian company, currently has three FDA-approved drugs: Juxtapid for homozygous familial hypercholesterolemia, Myalept for lipodystrophy and Mycapssa for acromegaly. It also has Filsuvez, which was approved in the EU in 2022.